Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response- a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trial

CONCLUSION: Sufficient cfDNA was detected in both plasma and ascites to study three biomarkers. These samples can provide useful information and should be considered in the design of future ovarian cancer trials.PMID:38417292 | DOI:10.1016/j.tranon.2024.101914

Source: Translational Oncology - February 28, 2024 Category: Cancer & Oncology Authors: Bonnita Werner Katrin M Sjoquist David Espinoza Sonia Yip Garry Chang Michelle M Cummins Linda Mileshkin Sumitra Ananda Catherine Shannon Michael Friedlander Kristina Warton Caroline E Ford Source Type: research